News | EP Lab | September 08, 2020

Study Shows Severe Fainting Can Be Treated with Cardiac Pacing Supported by Closed Loop Stimulation

Biotronik's closed loop stimulation (CLS) technology helps reduce unexplained fainting in patients with recurrent episodes due to skipped heartbeats. #ESC2020

September 8, 2020 - A new study presented at the 2020 European Society of Cardiology (ESC) Congress shows that Biotronik's closed loop stimulation (CLS) technology helps reduce unexplained fainting in patients with recurrent episodes due to skipped heartbeats.

The BIOSync study found that dual-chamber pacemaker supported by the CLS algorithm is highly effective in reducing the recurrence of asystolic vasovagal syncope – caused by temporary pause in the heart beat.[1]

The multi-center study – the largest of its kind - was a double-blind, randomized and placebo controlled trial conducted across 24 sites in Italy, France, Spain, Portugal, Netherlands and Canada between 2015 and 2020, with a medium follow-up of 11.2 months. It had a sample size of 127 patients.

A vasovagal reflex is a frequent cause of unexplained loss of consciousness. In extreme cases this results in an asystolic pause which leads to severe syncope events. In addition to the impact caused by these syncopes on patients' health, patients can become increasingly distressed due to the high frequency and unpredictable nature of these events – further hindering their quality of life.

When comparing the CLS-paced group versus the control group, the BIOSync study found that after two years:

Syncope recurrence rate was reduced by 77 per cent, and The combined rate of syncope and/or pre-syncope was reduced by 56 per cent.

Additionally, until this study, the use of tilt-table testing to select patients with severe recurrent reflex syncope for cardiac pacing was controversial. The positive results demonstrated through this trial indicate that asystolic response to these tests is a valuable criterion for cardiac pacing. 

"Dual-chamber pacemaker with CLS has the potential to provide significant relief for patients suffering from severe unexplained syncope," said Prof. Michele Brignole, Istituto Auxologico Italiano, Ospedale San Luca in Italy, principal investigator of the BIOSync study. "Patients who have tried alternative therapies with no success, can now efficiently be treated through pacing, giving them more options to treat their distressing condition."

"This trial provided promising results in the ability to use tilt-testing as a method for selecting pacemaker candidates and will help avoid delays in diagnosis and treatment for patients," said Dr. Marco Tomaino, Central Hospital of Bolzano, Italy, co-chairman of the BIOSync study.

Biotronik's CLS is an algorithm which identifies changes in a patient's cardiac contractility and translates this data to deliver proper heart rate adaptation, promoting more effective physiological therapy. This technology is exclusive to Biotronik.

Find more news from the ESC meeting

 

References:

1. The Benefit of Dual-Chamber Pacing with Closed Loop Stimulation in Tilt-Induced Cardioinhibitory Reflex Syncope (BIOSync CLS) study, reference number: NCT02324920.
 

 


Related Content

News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
News | EP Lab

April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...

Home April 21, 2025
Home
News | EP Lab

Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home February 14, 2025
Home
News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...

Home June 25, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
News | EP Lab

January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...

Home January 11, 2024
Home
Subscribe Now